Candriam S.C.A. Boosts Position in Abbott Laboratories $ABT

Candriam S.C.A. lifted its position in Abbott Laboratories (NYSE:ABT) by 12.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,172,360 shares of the healthcare product maker’s stock after purchasing an additional 125,477 shares during the quarter. Abbott Laboratories comprises about 0.8% of Candriam S.C.A.’s holdings, making the stock its 17th biggest holding. Candriam S.C.A. owned approximately 0.07% of Abbott Laboratories worth $157,026,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Carr Financial Group Corp increased its position in shares of Abbott Laboratories by 2.0% during the 3rd quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock worth $520,000 after purchasing an additional 76 shares during the last quarter. Tortoise Investment Management LLC increased its position in shares of Abbott Laboratories by 10.7% during the second quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock valued at $108,000 after acquiring an additional 77 shares during the last quarter. Gemmer Asset Management LLC raised its stake in shares of Abbott Laboratories by 2.9% in the 3rd quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock valued at $368,000 after acquiring an additional 78 shares during the period. Bridgewater Advisors Inc. boosted its position in shares of Abbott Laboratories by 0.6% during the 2nd quarter. Bridgewater Advisors Inc. now owns 12,555 shares of the healthcare product maker’s stock worth $1,607,000 after purchasing an additional 79 shares during the period. Finally, Nia Impact Advisors LLC increased its holdings in Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after purchasing an additional 79 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Up 1.6%

ABT stock opened at $110.86 on Monday. The company’s 50 day moving average price is $120.86 and its 200 day moving average price is $126.91. The firm has a market capitalization of $192.77 billion, a price-to-earnings ratio of 29.80, a PEG ratio of 1.76 and a beta of 0.75. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $141.23. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is 67.74%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ABT. Argus lowered their price target on Abbott Laboratories from $150.00 to $140.00 in a research report on Tuesday, January 27th. Sanford C. Bernstein lowered their target price on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Piper Sandler cut their price target on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research note on Friday, January 23rd. Daiwa Securities Group lowered their price objective on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Finally, Weiss Ratings cut shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $137.05.

Insider Activity at Abbott Laboratories

In other news, Director Daniel J. Starks bought 10,000 shares of Abbott Laboratories stock in a transaction dated Wednesday, February 4th. The stock was acquired at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the acquisition, the director owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.